Related Experiment Video
Updated: Jan 14, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Clinical Correlates of a Ratio-Based Progression Index in Parkinson's Disease: Insights from a Large Cross-Sectional
Halil Onder1, Ismet Melek1, Rifat Bozkus2
1Department of Neurology, Etlik City Hospital, Ankara, Turkey.
Background:
Assessment of disease progression in Parkinson's disease (PD) usually relies on longitudinal follow-up, which is often impractical in large real-world cohorts. Cross-sectional approaches may provide pragmatic proxies to explore relative motor deterioration using routine clinical data.
Objectives:
To explore clinical and non-motor correlates of estimated relative motor progression in PD using a simple ratio-based index-MDS-UPDRS Part III (OFF medication) divided by disease duration.
Methods:
In this retrospective cross-sectional study, 711 patients with idiopathic PD were classified as slow or fast progressors based on the cohort median of the MDS-UPDRS III (OFF)/disease duration ratio (7.31 points/year). Motor, non-motor, demographic, and treatment-related variables were compared between groups. Multivariable logistic regression analyses were used to identify clinical features associated with higher estimated progression.
Results:
Patients with higher estimated motor burden per year showed greater non-motor symptom burden, higher residual motor load (ON/OFF ratio), and a higher prevalence of the akinetic-rigid phenotype. In multivariable analyses, non-motor symptom burden, residual motor ratio, shorter disease duration, and akinetic-rigid phenotype were independently associated with higher estimated progression. Among non-motor domains, Sleep/Fatigue and Miscellaneous symptoms showed specific associations. The models demonstrated good within-cohort explanatory performance (Nagelkerke R2 = 0.42-0.47) in this cross-sectional cohort.
Conclusions:
This study presents a simple ratio-based proxy to explore relative motor progression in PD. While not a validated longitudinal progression measure, it may serve as a pragmatic exploratory tool for descriptive stratification of large clinical cohorts. Longitudinal validation is required.
More Related Videos
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
04:08Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
Published on: January 18, 2021
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...